This review highlights the importance of assessing liver inflammation in NAFLD with non-invasive biomarkers, especially in the drug development process, owing to the inaccuracies of liver biopsies. LiverMultiScan’s cT1 emerges as a robust biomarker that correlates with necroinflammation, fibrosis, and liver-related clinical outcomes, with fewer technical failures than ultrasound-based techniques.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?